Are you an innovator or a follower? There is no right or wrong answer. Just know which you are. Otherwise, you are getting in the way. Image via Unsplash

Everyone likes to consider themselves innovators, or at least believe that innovation is happening in their domain. But innovation management is a process that requires leaders to commit deeply and believe that the risk is worth the reward.

For many business leaders, regardless of the industry, it can be a struggle to embrace creativity and innovation and to commit the needed resources of time, funding, and staff to develop new methods of doing business. For many, it is a conflict to invest when there is not a clear, immediate, or guaranteed financial return on investment. When it comes to innovation, the biggest return on investment can be the learnings and the mindset shift, not just the financial gains.

Leaders need to ask themselves a couple of questions:

“Do I want to be an innovator or a follower?” There is no right answer as both leaders and followers are needed. But one thing to keep in mind is that innovation without failure is impossible.

Thus, the next question emerges: “Which do I value more, taking reasonable risks and learning or being a mainstream adopter?” And again, there is no right answer.

Seth Godin, author and former dot com executive, once said, “No organization ever created an innovation. People innovate, not companies.”

With that in mind, for those who genuinely want to be leaders of innovation, there are certain “must-haves” for any process. The most important “must-haves” are remembering that internal culture impacts success and support from the top down is absolutely integral.

Real innovation moves the organization forward strategically. 

Designate ownership and accountability to measure progress. These measurements will often look quite different from other success metrics, are often more opaque and are even not immediately financial. These non-financial metrics sometimes make team members feel uncomfortable, and that is okay. Ultimately everyone involved in this process needs to be willing to hear truth and be committed to creating a culture that drives creativity.

Innovation has a clear alignment with organizational business strategy. 

Leadership and designated team members need defined problems to solve that align with the stated business strategies. There is no point innovating a widget or process that does not move the organization forward.

Innovation requires a defined process and funding. 

Leadership should begin by carving out one full year of budget solely dedicated to innovation and trying new things. These dedicated resources include funding, full-time employees, and support from a consultant, such as EPIcenter, to challenge leaders and drive the process. There must be buy-in by the team members with leaders committed to ongoing sightlines of the process.

The right team members need to be at the table.

The right people need to be the ones to make decisions, evaluate innovations and de-risk both the technology and the business models to make things happen. The team should include individuals who are adaptive and tenured, new and nimble, and a mix of subject matter expertise and enthusiasm.

Innovation success requires the right mindset.

Both the leadership and innovation team must have a mantra of “how can we” rather than “we can’t” or “we’ve never done it that way before” or “it failed before.” There must be a will and desire to work, innovate, fail, resolve, and execute -- or at least learn.

Sometimes innovative solutions emerge by happenstance during the process without a known or stated problem. With proper training and a curious mindset anything is possible.

With these requirements in mind, let’s go back to the initial questions asked of business leaders, but in reverse order this time:

“What do you value more, taking reasonable risks and learning while meeting strategic goals or pure financial gain?”

“Are you okay with failure, adjustments and trying again?”

“Are you an innovator or a follower?”

Again, there is no right or wrong answer. Just know which you are. Otherwise, you are getting in the way.

------

Liz Thompson serves as the chief of advisory services at EPIcenter, a Texas-based nonprofit organization with a think tank, incubator, and accelerator focused on energy innovation and thought for the global future.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Houston femtech co. debuts new lactation and wellness pods

mom pod

Houston-based femtech company Work&, previously known as Work&Mother, has introduced new products in recent months aimed at supporting working mothers and the overall health of all employees.

The company's new Lactation Pod and Hybrid Pod serve as dual-use lactation and wellness spaces to meet employer demand, the company shared in a news release. The compact pods offer flexible design options that can serve permanent offices and nearly all commercial spaces.

They feature a fully compliant lactation station while also offering wellness functionalities that can support meditation, mental health, telehealth and prayer. In line with Work&'s other spaces, the pods utilize the Work& scheduling platform, which prioritizes lactation bookings to help employers comply with the PUMP Act.

“This isn’t about perks,” Jules Lairson, Work& co-founder and COO, said in the release. “It’s about meeting people where they are—with dignity and intentional design. That includes the mother returning to work, the employee managing anxiety, and everyone in between.”

According to the company, several Fortune 500 companies are already using the pods, and Work& has plans to grow the products' reach.

Earlier this year, Work& introduced its first employee wellness space at MetroNational’s Memorial City Plazas, representing Work&'s shift to offer an array of holistic health and wellness solutions for landlords and tenants.

The company, founded in 2017 by Lairson and CEO Abbey Donnell, was initially focused on outfitting commercial buildings with lactation accommodations for working parents. While Work& still offers these services through its Work&Mother branch, the addition of its Work&Wellbeing arm allowed the company to also address the broader wellness needs of all employees.

The company rebranded as Work& earlier this year.

Rice biotech studio secures investment from Modi Ventures, adds founder to board

fresh funding

RBL LLC, which supports commercialization for ventures formed at the Rice University Biotech Launch Pad, has secured an investment from Houston-based Modi Ventures.

Additionally, RBL announced that it has named Sahir Ali, founder and general partner of Modi Ventures, to its board of directors.

Modi Ventures invests in biotech companies that are working to advance diagnostics, engineered therapeutics and AI-driven drug discovery. The firm has $134 million under management after closing an oversubscribed round this summer.

RBL launched in 2024 and is based out of Houston’s Texas Medical Center Helix Park. William McKeon, president and CEO of the TMC, previously called the launch of RBL a “critical step forward” for Houston’s life sciences ecosystem.

“RBL is dedicated to building companies focused on pioneering and intelligent bioelectronic therapeutics,” Ali said in a LinkedIn post. “This partnership strengthens the Houston biotech ecosystem and accelerates the transition of groundbreaking lab discoveries into impactful therapies.”

Ali will join board members like managing partner Paul Wotton, Rice bioengineering professor Omid Veiseh, scientist and partner at KdT Ventures Rima Chakrabarti, Rice alum John Jaggers, CEO of Arbor Biotechnologies Devyn Smith, and veteran executive in the life sciences sector James Watson.

Ali has led transformative work and built companies across AI, cloud computing and precision medicine. Ali also serves on the board of directors of the Drug Information Association, which helps to collaborate in drug, device and diagnostics developments.

“This investment by Modi Ventures will be instrumental to RBL’s growth as it reinforces confidence in our venture creation model and accelerates our ability to develop successful biotech startups,” Wotton said in the announcement. "Sahir’s addition to the board will also amplify this collaboration with Modi. His strategic counsel and deep understanding of field-defining technologies will be invaluable as we continue to grow and deliver on our mission.”